Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study.
COVID-19
SARS-CoV-2
angiogenic factors
preeclampsia
preeclampsia-like syndrome
pregnancy
soluble fms-like tyrosine kinase-1–to–placental growth factor ratio
Journal
American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
19
08
2022
revised:
28
09
2022
accepted:
28
09
2022
pubmed:
5
10
2022
medline:
21
12
2022
entrez:
4
10
2022
Statut:
ppublish
Résumé
Since the outbreak of the COVID-19 pandemic, some studies have reported an increased preeclampsia incidence in pregnant women with SARS-CoV-2 infection. Several explanations for this association have been proposed, including a preeclampsia-like syndrome induced by severe COVID-19. This syndrome was described in a small case series and has not been confirmed in larger studies, and its effect on perinatal outcomes has not been studied. This study aimed to confirm the preeclampsia-like syndrome because of COVID-19 and to investigate its implications on pregnancy outcomes and prognosis. This was a prospective, observational study conducted in a tertiary referral hospital. The inclusion criteria were pregnant women admitted to the intensive care unit for severe pneumonia because of COVID-19. They were classified into 3 groups based on clinical and laboratory findings: preeclampsia, preeclampsia-like syndrome, and women without preeclampsia features. The 3 cohorts were analyzed and compared at 3 different times: before, during, and after severe pneumonia. The main outcomes were incidence of adverse perinatal outcomes and signs and symptoms of PE, such as hypertension, proteinuria, thrombocytopenia, elevated liver enzymes, and increased angiogenic factors (soluble fms-like tyrosine kinase 1-to-placental growth factor ratio). A total of 106 women were admitted to the intensive care unit because of severe pneumonia, and 68 women were included in the study. Of those, 53 (50.0%) did not meet the diagnostic criteria for preeclampsia and remained pregnant after pneumonia (non-preeclampsia); 7 (6.6%) met the diagnostic criteria for preeclampsia, had abnormal (>38) soluble fms-like tyrosine kinase 1-to-placental growth factor ratio (preeclampsia), and delivered during severe pneumonia, and 8 (7.5%) met the diagnostic criteria for preeclampsia, had normal (≤38) soluble fms-like tyrosine kinase 1-to-placental growth factor ratio (preeclampsia like), and did not deliver during pneumonia. Despite not having delivered, most preeclampsia-related features improved after severe pneumonia in women with preeclampsia-like syndrome. Women with preeclampsia had significantly poorer outcomes than women with preeclampsia-like syndrome or without preeclampsia. More than 50% of women with severe COVID-19 and diagnostic criteria for preeclampsia may not be preeclampsia but a preeclampsia-like syndrome, which may affect up to 7.5% of women with severe COVID-19. Preeclampsia-like syndrome might have similar perinatal outcomes to those of normotensive women with severe pneumonia because of COVID-19. For these reasons, preeclampsia-like syndrome should be excluded by using soluble fms-like tyrosine kinase 1-to-placental growth factor ratio in future research and before making clinical decisions.
Sections du résumé
BACKGROUND
Since the outbreak of the COVID-19 pandemic, some studies have reported an increased preeclampsia incidence in pregnant women with SARS-CoV-2 infection. Several explanations for this association have been proposed, including a preeclampsia-like syndrome induced by severe COVID-19. This syndrome was described in a small case series and has not been confirmed in larger studies, and its effect on perinatal outcomes has not been studied.
OBJECTIVE
This study aimed to confirm the preeclampsia-like syndrome because of COVID-19 and to investigate its implications on pregnancy outcomes and prognosis.
STUDY DESIGN
This was a prospective, observational study conducted in a tertiary referral hospital. The inclusion criteria were pregnant women admitted to the intensive care unit for severe pneumonia because of COVID-19. They were classified into 3 groups based on clinical and laboratory findings: preeclampsia, preeclampsia-like syndrome, and women without preeclampsia features. The 3 cohorts were analyzed and compared at 3 different times: before, during, and after severe pneumonia. The main outcomes were incidence of adverse perinatal outcomes and signs and symptoms of PE, such as hypertension, proteinuria, thrombocytopenia, elevated liver enzymes, and increased angiogenic factors (soluble fms-like tyrosine kinase 1-to-placental growth factor ratio).
RESULTS
A total of 106 women were admitted to the intensive care unit because of severe pneumonia, and 68 women were included in the study. Of those, 53 (50.0%) did not meet the diagnostic criteria for preeclampsia and remained pregnant after pneumonia (non-preeclampsia); 7 (6.6%) met the diagnostic criteria for preeclampsia, had abnormal (>38) soluble fms-like tyrosine kinase 1-to-placental growth factor ratio (preeclampsia), and delivered during severe pneumonia, and 8 (7.5%) met the diagnostic criteria for preeclampsia, had normal (≤38) soluble fms-like tyrosine kinase 1-to-placental growth factor ratio (preeclampsia like), and did not deliver during pneumonia. Despite not having delivered, most preeclampsia-related features improved after severe pneumonia in women with preeclampsia-like syndrome. Women with preeclampsia had significantly poorer outcomes than women with preeclampsia-like syndrome or without preeclampsia.
CONCLUSION
More than 50% of women with severe COVID-19 and diagnostic criteria for preeclampsia may not be preeclampsia but a preeclampsia-like syndrome, which may affect up to 7.5% of women with severe COVID-19. Preeclampsia-like syndrome might have similar perinatal outcomes to those of normotensive women with severe pneumonia because of COVID-19. For these reasons, preeclampsia-like syndrome should be excluded by using soluble fms-like tyrosine kinase 1-to-placental growth factor ratio in future research and before making clinical decisions.
Identifiants
pubmed: 36195282
pii: S2589-9333(22)00190-2
doi: 10.1016/j.ajogmf.2022.100760
pmc: PMC9526511
pii:
doi:
Substances chimiques
Placenta Growth Factor
144589-93-5
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100760Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Am J Obstet Gynecol. 2022 Feb;226(2S):S786-S803
pubmed: 35177220
Semin Perinatol. 2009 Jun;33(3):196-205
pubmed: 19464511
CEN Case Rep. 2019 May;8(2):95-100
pubmed: 30565047
Am J Obstet Gynecol. 2022 Feb;226(2):280-281
pubmed: 34534500
Clin Biochem. 2010 Jun;43(9):768-70
pubmed: 20206155
N Engl J Med. 2020 Jun 18;382(25):e100
pubmed: 32302077
N Engl J Med. 2022 May 12;386(19):1817-1832
pubmed: 35544388
Ultrasound Obstet Gynecol. 2008 Aug;32(2):128-32
pubmed: 18457355
Am J Obstet Gynecol. 2022 Feb;226(2):279-280
pubmed: 34619111
Br J Obstet Gynaecol. 1975 Sep;82(9):702-10
pubmed: 1182090
Am J Obstet Gynecol MFM. 2020 May;2(2):100107
pubmed: 32292902
Obstet Gynecol. 2013 Nov;122(5):1122-1131
pubmed: 24150027
Case Rep Endocrinol. 2012;2012:586056
pubmed: 22937297
Am J Obstet Gynecol. 2012 Jan;206(1):58.e1-8
pubmed: 22000672
BMC Pregnancy Childbirth. 2015 Aug 25;15:189
pubmed: 26303772
Am J Obstet Gynecol. 2021 Sep;225(3):289.e1-289.e17
pubmed: 34187688
Am J Obstet Gynecol. 2022 Jan;226(1):68-89.e3
pubmed: 34302772
Kidney Int. 2013 Jan;83(1):177-81
pubmed: 23014459
BMC Pregnancy Childbirth. 2009 Feb 26;9:8
pubmed: 19245695
BJOG. 2020 Oct;127(11):1374-1380
pubmed: 32479682
JAMA Pediatr. 2021 Aug 1;175(8):817-826
pubmed: 33885740
Ultrasound Obstet Gynecol. 2022 Feb;59(2):146-152
pubmed: 34766403